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Left Ventricular Systolic and Diastolic Dysfunction
after Infusion of Tumor Necrosis Factor-a in Conscious Dogs
Francis D. Pagani, Lauren S. Baker, Charles Hsi, Mark Knox, Mitchell P. Fink, and Marc S. Visnert
University ofMassachusetts Medical Center, Department ofSurgery, Worcester, Massachusetts 01655
Abstract
We used a load-insensitive index of systolic left ventricular
(LV) function and an analysis of diastolic pressure-dimension
relationships to test the hypothesis that recombinant human
(rh) tumor necrosis factor-a (TNFa) impairs LV function in
dogs. Animals were studied 7-10 d after aseptic implantation of
instrumentation to monitor cardiac output, external anterior-
posterior LV diameter, and LV and pleural pressures. Data
were analyzed from seven dogs that received active rhTNFa
(100 Mg/kg over 60 min) and from five dogs that received heat-
inactivated rhTNFa. At 24 h after infusion of active rhTNFa,
the slope of the LV end-diastolic dimension-stroke work rela-
tionship decreased significantly, indicating a decrement in LV
systolic contractility. Simultaneously, LV unstressed dimen-
sion increased significantly, suggesting diastolic myocardial
creep. The end-diastolic relationship between LV transmural
pressure and normalized LV dimension (strain) was markedly
displaced to the left, suggesting increased diastolic elastic stiff-
ness. Despite these changes in LV performance, cardiac index
was maintained by tachycardia. The abnormalities in LV func-
tion were resolved by 72 h. We conclude that rhTNFa reversi-
bly impairs LV systolic and diastolic function in unanesthetized
dogs. Because dysfunction occurs > 6 h after the infusion of
rhTNFa and persists for 24-48 h, the mechanism underlying
this phenomenon may involve secondary mediators or a change
in myocardial gene expression. (J. Clin. Invest. 1992. 90:389-
398.) Key words: cytokine - myocardial contractility * myocar-
dial blood flow . myocardial creep * myocardial stiffness
Introduction
Recent clinical and experimental studies strongly support the
hypothesis that tumor necrosis factor-a (TNFa)' is a mediator
oforgan dysfunction and shock induced by sepsis and endotox-
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1. Abbreviations used in this paper: BEL, ventricular dimension at be-
ginning ejection; CM, tissue microsphere count; CR, reference micro-
sphere count; e, Lagrangian strain; EDL, ventricular dimension at end
diastole; EEL, ventricular dimension at end ejection; %ES, fractional
ejection shortening ofleft ventricular minor axis diameter; L, ventricu-
lar minor axis dimension; 4, unstressed ventricular dimension; Lw,
x-intercept ofthe preload recruitable stroke-work relationship; LV, left
emia. Elevated plasma levels ofTNFa are present in patients
with a variety of infectious diseases (1), and plasma levels of
TNFa correlate with morbidity and mortality due to meningi-
coccal meningitis (2). Administration of lipopolysaccharide
(LPS) to humans (3) or animals (4, 5), and infusion of live
bacteria in animals (6, 7) increases plasma levels of TNFa.
Administration ofTNFa to humans (8, 9), mice ( 10, 11 ), rats
( 12-16), rabbits ( 17), dogs ( 18-20), and sheep (21, 22) elicits
manifestations of sepsis and septic shock, including fever, hy-
potension, acidosis, leukopenia, histopathological evidence of
organ injury, and death. In experimental animals, survival is
improved when monoclonal (23) or polyclonal (24) antibod-
ies against TNFa are administered before challenge with live
Escherichia coli or LPS.
Studies in patients (25-28) and experimental animals (29-
32) indicate that alterations in myocardial performance are
characteristic of sepsis and septic shock. Both left ventricular
(LV) systolic dysfunction (depressed ejection fraction) and dia-
stolic dysfunction (decreased chamber compliance) have been
documented. Recent data suggest that TNFa is one ofthe medi-
ators of sepsis-induced cardiac dysfunction. Recombinant hu-
man (rh) TNFa induces myocardial depression in dogs (19)
and guinea pigs (S. 0. Heard, M. W. Perkins, and M. P. Fink,
personal communication), and suppresses the positive inotro-
pic effect of isoproteronol in cultured murine fetal heart
cells (34).
The purpose of the present study was to rigorously test the
hypothesis that rhTNFa impairs LV systolic and diastolic
function in chronically instrumented conscious dogs. Alter-
ations in systolic LV function were assessed by analyzing
changes in the preload recruitable stroke-work relationship.
This relationship is a load-insensitive index of systolic myocar-
dial function that relates increases in LV stroke work to in-
creases in preload (end-diastolic volume or dimension) (35).
Changes in the diastolic properties of the left ventricle were
assessed by analyzing diastolic transmural pressure-dimension
and transmural pressure-strain relationships. A preliminary
report of these data has been published (36).
Methods
Surgical preparation. 22 adult mongrel dogs (20-33 kg) were anesthe-
tized with thiopental sodium (25 mg/kg; Abbott Laboratories, North
Chicago, IL) and maintained on 1% halothane (Halocarbon Laborato-
ries, Inc., North Augusta, SC) and pancuronium bromide (0.05 mg/
ventricular; Msw, slope of the preload recruitable stroke-work rela-
tionship; PA, arterial pressure; PLV, left ventricular intracavitary pres-
sure; PPL, intrapleural pressure; PRA, right atrial pressure; PT, left
ventricular transmural pressure; Q, cardiac output indexed to body
weight; QM, myocardial blood flow; QR, reference blood flow;
rhTNFa, recombinant human tumor necrosis factor-a; SVRI, sys-
temic vascular resistance index; SW, stroke work; TNFa, tumor necro-
sis factor-a.
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kg; Quad Pharmaceutical, Inc., Indianapolis, IN). All animals received
intravenous cefazolin (500 mg; Eli Lilly& Co., Indianapolis, IN) preop-
eratively. A left thoracotomy was performed through the fifth intercos-
tal space, and the pericardium was opened and suspended to expose the
heart. A pair of ultrasonic dimension transducers (Physiologic Moni-
toring Systems Group, Durham, NC) were implanted on the LV epi-
cardium adjacent to the anterior and posterior descending coronary
arteries to measure the external LV anterior-posterior minor axis diam-
eter (Fig. 1 ). A pulsed transit time ultrasonic flow probe (model 14348,
12 or 14 mm o.d.; Transonic Systems Inc., Ithaca, NY) was implanted
around the pulmonary artery to monitor cardiac output. A silicone
rubber catheter (2.6 mm i.d., 4.9 mm o.d.; Dow Corning, Midland,
MI) was implanted in the base ofthe left atrium for injection of micro-
spheres and passage of a catheter-tipped micromanometer to measure
LV intracavitary pressure (PLv) during subsequent studies. Another
silicone rubber catheter was implanted in the right atrial appendage for
measuring right atrial pressure (PRA) and sampling venous blood. A
third silicone rubber catheter, closed at its distal end by a compliant
silicone rubber balloon (1/1I00 in thickness), was positioned in the
chest at the level ofthe aortic arch for subsequent passage ofa microma-
nometer to measure intrapleural pressure (PPL). Inflatable silicone
rubber occluders (Isis Inc., Minneapolis, MN) were placed around the
venae cavae for performing transient vena caval occlusions. The azy-
gous vein was ligated to insure cessation ofvenous inflow during vena
caval occlusions. A fluid-filled polyvinyl chloride catheter was inserted
through the left internal mammary artery into the aortic arch to mea-
sure arterial pressure (PA) and to collect arterial blood samples. The
electrical leads, catheters, and occluders were all exteriorized dorsal to
the thoracotomy incision. A 20 French thoracostomy tube was im-
planted for postoperative evacuation of fluid and air. The pericardium
was left open, and the chest was closed. Postoperatively, all animals
received dihydrostreptomycin (0.05 g i.m.) and procaine penicillin
(400,000 U i.m.) daily for 6 d (Pfizer Inc., New York). Thoracostomy
tubes were removed on the third to fifth postoperative day. The ani-
mals were monitored according to the guidelines of the Committee on
Animal Research of the University of Massachusetts Medical Center
and those prepared by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources, National
Council (DHEW Publication No. [NIH] 85-23, revised 1985).
Instrumentation and data acquisition. Animals were allowed to re-
cover for 7-10 d before being studied. Data were collected with the
LA
Catheter
animals awake and unsedated. PLV and PPL were measured using high
fidelity micromanometers (model MPC 500; Millar, Inc., Houston,
TX) inserted through the left atrial and pleural catheters, respectively.
The micromanometers were zeroed and balanced to atmospheric pres-
sure at 38°C. Pressures in the ascending aorta and right atrium were
measured using external transducers (model 800; Bentley Trantec, Elk
Grove, IL) connected to the fluid-filled catheters that had been im-
planted in the aorta and right atrium, respectively. Cardiac rhythm was
monitored from lead II of the electrocardiogram.
The ultrasonic dimension transducers were coupled to a sonomi-
crometer (James W. Davis, Inc., Durham, NC) with a minimal resolu-
tion of 0.08 mm, and maximal electronic drift of 0.05 mm/h. The
ultrasonic flow probe on the pulmonary artery was coupled to a pulsed
transit time flowmeter (Transonic Systems, Inc., Ithaca, NY). Analog
signals representing pressures and flow were passed through a series of
preamplifiers (Litton Medical Electronics, Inc., Elk Grove, IL) and,
together with the signals representing dimension and flow were pro-
cessed by medium gain amplifiers (James W. Davis, Inc.). The signals
were recorded on an eight-channel FM tape recorder (AP Vetter Co.,
Rebersburg, PA) and simultaneously digitized at a sweep rate of 200
Hz per channel using an analog-to-digital converter (model 1012;
ADAC, Woburn, MA) interfaced with a PDP 11/73 computer (Digital
Equipment Corp., Maynard, MA).
Experimental Protocol. After the surgical implantation of instru-
mentation, rectal temperature (T) and body weight were monitored
daily. At the time ofeach study, recordings ofheart rate (HR), PA, PRA,
PLv, PPL, LV dimension, and cardiac output were acquired. Arterial
blood samples were obtained for determination of pH, Pco2, and Po2
(System 1302 blood gas analyzer; Instrumentation Laboratories, Inc.,
Lexington, MA), and lactate concentration (model 23L lactate ana-
lyzer, Yellow Springs Instrument Co., Yellow Springs, OH). Venous
blood samples were obtained for determination of plasma concentra-
tion of the stable prostacyclin metabolite, 6-keto-PGFIa (37). Signals
were then recorded during transient vena caval occlusions, performed
over 30 s to bring peak systolic PLV to 30 mmHg.
Baseline data were acquired on the day before rhTNFa administra-
tion (day -1 ) and just before administration (day 0). Animals then
received either 100 ug/kg of recombinant human rhTNFa or 100 ,ug/
kg of heat-inactivated rhTNFa (denatured by boiling for 30 min).
Recombinant human TNFa (lot EB601 1) was supplied by Knoll Phar-
maceuticals Inc., Whippany, NJ. Specific activity was 1 X 107 U/mg
Flow
RA Ca
Anterior
, Ultrasonic
Crystal
Ultrasonic
Crystal
Figure 1. Implantation of instrumentation to monitor cardiac output (pulmonary artery flow probe), external LV anterior-posterior dimension
(ultrasonic crystals), aortic and right atrial pressures (fluid-filled catheters). LV pressure was measured with a micromanometer introduced
through an implanted left atrial catheter. Inflatable vena caval occluders permitted the adjustment ofLV loading during experiments.
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protein, and the LPS content was < 0.5 ng/mg protein (manufac-
turer's data). Individual doses of active rhTNFa or heat-inactivated
rhTNFa were reconstituted in 20 ml of saline and administered over I
h. The administration tubing and syringes were treated with 3 ml ofdog
plasma before each infusion. Animals received infusions of normal
saline before each study to bring end-diastolic PLv to its baseline level.
After administration of active or heat-inactivated rhTNFa, data were
obtained at 3 and 6 h, and at 1,2, 3, 5, and 7 d (data from days 3 and 5
are not presented). Myocardial blood flows were determined by inject-
ing color-coded microspheres through the left atrial catheter and sam-
pling blood from the aortic catheter on days 0, 2, and 7. Aerobic and
anaerobic blood cultures were obtained from a peripheral vein on days
0, 2, and 7.
At the conclusion ofthe experiments, the animals were euthanized,
and the positions of the ultrasonic dimension transducers were con-
firmed at autopsy. For the purpose of determining myocardial blood
flow, the left ventricle was sectioned into four concentric rings of ap-
proximately equal thickness in the plane of the minor axis. The middle
two rings were divided into three regions representing the interventricu-
lar septum, anterior free wall, and posterolateral free wall. These sam-
ples were dissected into epicardial, midmyocardial, and endocardial
sections. The epicardial and endocardial thirds (weighing 2-3 g) were
then chemically digested, and the number ofspheres was determined in
each sample (38).
Data analysis. The first derivative ofPLv (dP/dt) was calculated as
a running five-point orthogonal polynomial approximation from the
digital pressure waveform. Diastolic and ejection phases of the cardiac
cycle were defined using interactive software. The beginning of dia-
stolic filling was defined as the first zero crossing of the dP/dt wave-
form following peak negative dP/dt (39). End diastole was defined as
the upstroke of the R wave of the electrocardiogram (39). Beginning
ejection was defined as the point 10 ms after peak positive dP/dt (39).
End ejection was defined as the point 20 ms before peak negative dPI
dt (39, 40). Only data from the mid- to end-expiratory phase of the
respiratory cycle were considered for analysis to minimize respiratory
variation in PLv and LV dimension.
LV transmural pressure (PTm) was calculated as the difference be-
tween PLv and PPL: PTM = PLv - PPL.
An analogue of LV stroke work (SW) was calculated for individual
cardiac cycles as the integral of PTm versus LV anterior-posterior
minor axis dimension. Fractional global ejection shortening (%ES) was
defined as the change in LV minor axis dimension during the ejection
phase of the cardiac cycle normalized to end-diastolic dimension: %ES
= (BEL - EEL)/EDL where BEL, EEL, and EDL are beginning ejec-
tion, end ejection, and end-diastolic dimension, respectively.
For the purpose of characterizing systolic LV contractility, tran-
sient vena caval occlusions were performed to permit the construction
of the relationship between SW and LV end-diastolic dimension over a
wide range of loading. Data were fit by linear least squares regression to
the equation: SW = Msw (EDL - Lw), where Msw and Lw are the
derived slope and x-intercept, respectively. Only that portion of the
vena caval occlusion in which HR changed by < 10% was considered
for analysis.
For the purpose of assessing the passive diastolic compliance of the
LV chamber, measured anterior-posterior minor axis dimension was
normalized to a Lagrangian strain (E; fractional extension from un-
stressed dimension): = (L - LO)/ILO, where e is the Lagrangian strain
of dimension L, and 4 is the unstressed diastolic dimension, deter-
mined at maximal vena caval occlusion, when PTM was equal to 0
mmHg.
Diastolic compliance ofthe left ventricle was determined by analyz-
ing the relationship between end-diastolic PTm and strain. These data
were fit by nonlinear least squares regression to the equation: PTm = a
(el - 1), where a and fi are elastic constants determined from the
curve fit (41 ). To compare the pressure-strain relationships of the two
experimental groups, the derived a and # values were used to compute
strains at LV transmural pressures of 5, 10, and 15, and 20 mmHg. For
each group, means and standard deviations of the values of strain at
each pressure were then computed. For the purpose of illustration,
exponential forms were also fit to the relationship between end-diasto-
lic PTM and end-diastolic raw dimension (L), again using nonlinear
least squares regression: PTM = a (eOLe-e).
Determination of cardiac output and systemic vascular resistance:
Cardiac output indexed to body weight (CQ) was computed by dividing
the mean pulmonary artery flow measurement by body weight. Sys-
temic vascular resistance index (SVRI) was calculated as: SVRI = (PA
PRA)/Q-
Assay for plasma levels of 6-keto-PGFIa. Venous blood samples
were collected into iced-glass tubes containing 100 jig ofindomethacin
and 10.5 mg ofEDTA. Samples were then centrifuged ( 1,500 g) at 40C
for 15 min. The plasma was collected and stored in polypropylene
tubes at -70'C until assayed. Details of the radioimmunoassay for
6-keto-PGFI. (stable hydrolysis product of prostacyclin) have been
reported previously (37). The lower limit of sensitivity for the assay is
30 pg/ml. All samples were run in a single assay to obviate interassay
variability.
Determination of myocardial blood flow. Microspheres were agi-
tated for 10 min before injection. 7-10 million spheres ( 15 Elm) were
injected through the left atrial catheter and flushed with 10 ml of nor-
mal saline. A reference arterial blood sample was obtained from the
aortic arch at a withdrawal rate of 13.8 ml/min beginning 5 s before
injection and continuing for 90 s. Myocardial blood flow, indexed per
gram of tissue (QM), was calculated as: QM = CM*QR/CR, where CM is
the microsphere count in the tissue sample, CR is the number ofspheres
in the blood reference sample, and QR is the withdrawal rate of the
reference sample.
Statistical analysis. Statistical analyses were performed using com-
mercially available software (SAS Institute, Inc., Cary, NC). For the
analyses of myocardial function, the calculated parameters from ten
cardiac cycles were averaged. Two-way analysis of variance (ANOVA)
with repeated measures was used to compare parameters to their base-
line values (at -24 h) over time (within groups) and to compare time-
matched parameters between groups (42). When statistically signifi-
cant differences were identified by ANOVA for group effects or group-
time interactions, Tukey's studentized range test for multiple
comparisons was used to compare means at individual time points
(43). When statistically significant differences within groups over time
were observed by ANOVA, single degree of freedom F-tests were used
to compare the means at each time with baseline. Bonferonni's correc-
tion was utilized to compensate for the increased risk of a type I error
with multiple comparisons (44). The null hypothesis was rejected forP
< 0.05. Data are presented throughout the tables as means± 1 SD.
Results
Disposition ofexperimental animals (Table I) . Of the 22 dogs
that underwent implantation of the instrumentation, six were
excluded because of technical failures or infectious complica-
tions. Of the 16 dogs entered into the study, 10 received active
rhTNFa and six received inactivated rhTNFa. Data from 12 of
these 16 animals were analyzed; seven that had received active
rhTNFa and five controls. Four of the five dogs that died had
positive blood cultures and were excluded from the final data
analysis. One of the five deaths (active rhTNFa group) oc-
curred at 72 h, immediately after passage of the manometer-
tipped catheter into the left ventricle. This death was attributed
to an embolic event, and because blood cultures in this animal
were negative at 0 and 48 h, data collected before death were
analyzed.
Metabolic and respiratory parameters (Table II). There
were no significant differences between groups at baseline for
these variables: temperature ( 101.9±0.7 vs. 102.0±0.60F for
control and rhTNFa groups, respectively), arterial pH, Po2,
Pco2, and bicarbonate. Controls had slightly higher blood lac-
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Table I. Disposition ofExperimental Animals
Category n
Instrumented animals 22
Animals excluded before study 6
Technical failures 2*
Infectious complications 4$
Animals included for entry into study 16
Group
rhTNFa Control
Animals studied 10 6
Survivors 6 5
Deaths 4(3§) 1§
Animals included for data analysis 7 5
Deaths occurred at 6 h (2) and 48 h (1) in the active rhTNFa group
and 6 h (1) in the controls. One death (72 h) in the active rhTNFa
group had negative blood cultures and was included in the final data
analysis. * Technical failures (instrumentation failure [2]). $ In-
fectious complications (pneumonia [2], empyema [1], unidentified
source [1]). § Animals excluded from the final data analysis because
of positive blood cultures (identified organisms: Enterobacter cloacae
[1]; Acinetobacter caloaceticus [1]; Staphylococcus aureus [1]; Pro-
pinibacteria [1]).
tate concentrations at baseline than did dogs in the rhTNFa
group.
Administration ofheat-inactivated rhTNFa was associated
with minimal changes in temperature ( 101.7±0.8, 101.6±0.5,
101.2±0.6, 101.3±0.9, and 102.9±0.40F at 3, 6, 24, 48 h, and 7
d, respectively), arterial blood gases, and arterial concentra-
tions ofbicarbonate ion and lactate. Infusion ofactive rhTNFa
elicited a marked febrile response at 3 and 6 h ( 104.8±1.1 and
103.2±0.1 'F, respectively, P < 0.05 as compared to baseline,
Table II. Effects ofrhTNFa on Arterial pH, Po2, Pco2,
Bicarbonate, and Lactate Concentration
Time pH P02 Pco2 Bicarbonate Lactate
h mmHg meqlliter
Control
-24 7.42±0.02 84±5 37±2 24±1 1.1±0.2
0 7.44±0.03 83±4 36±2 24±1 1.0±0.3
3 7.40±0.02 85±4 37±2 23±2 0.7±0.2
6 7.40±0.03 86±3 37±3 24±2 0.6±0.2*
24 7.42±0.01 84±5 36±3 24±2 0.7±0.2
48 7.41±0.02 92±3* 35±2 23±2 1.0±0.2
168 7.43±0.03 81±6 36±3 24±4 1.2±0.6
rhTNFa
-24 7.41±0.03 84±6 36±2 23±2 0.7±0.3*
0 7.42±0.02 85±5 35±2 23±1 0.7±0.1
3 7.40±0.04 78±6*$ 30±3** 19±2*$ 1.8±0.1*
6 7.28±0.07*$ 82±7 29±3*$ 14±3*$ 2.6±1.3*$
24 7.31±0.03*$ 83±7 28±6*$ 16±2*1 0.7±0.2
48 7.36±0.05*$ 85±5* 31±6* 21±6 0.5±0.1*
168 7.43±0.02 80±6 34±6 24±2 0.6±0.2
102.0±0.60F and time-matched value in the control group).
There were no significant differences in temperature at 24 and
48 h, and 7 d (101.2 ± 0.6, 101.3 ± 0.9, and 102.9 ± 0.4,
respectively). Metabolic acidosis was present 6 and 24 h after
infusion ofthe active cytokine. Arterial bicarbonate concentra-
tion was decreased at 3, 6, and 24 h; circulating lactate concen-
trations were increased at 3 and 6 h.
Compared to controls, arterial Po2 was transiently lower in
the rhTNFa group at 3 h. In the active rhTNFa group, arterial
Pco2 was decreased at 3, 6, 24, and 48 h, but recovered to
baseline at 72 h.
Hemodynamic variables (Table III). At baseline, hemody-
namic variables were comparable in the two groups. Adminis-
tration of heat-inactivated rhTNFa did not affect HR, peak
systolic PTM, end-diastolic PTM, PA, dP/dt, Q. or SVRI. In
contrast, infusion of active rhTNFa significantly increased
HR, peak systolic PTM, and dP/dt at 3 h. 6 h after the adminis-
tration of active rhTNFa, HR remained elevated, but peak
systolic PTM and dP/dt recovered to baseline values. At 24 h,
HR was elevated, whereas peak systolic PTM, dP/dt, PA, and
SVRI were significantly decreased from baseline. By 48 h, HR,
peak systolic PTm, PA, and SVRI were all similar to baseline
values, although dP/dt was still decreased compared to base-
line and compared to the time-matched value in the control
group. Except for significantly lower dP/dt in the active
rhTNFa group at 72 h (2,436±414 vs. 3,201±318 for rhTNFa
and control groups, respectively), there were no further signifi-
cant differences in hemodynamic variables between the two
groups.
In order to maintain end-diastolic PLV at its baseline value
during the course of each study, animals receiving active
rhTNFa required resuscitation with a larger (P < 0.05) volume
of normal saline as compared to baseline and time-matched
control values at 3, 6, and 24 h (17±10 vs. 18±18, 2±3 vs.
34±14, 2±4 vs. 39±20, 4±6 vs. 65±27, 12±12 vs. 24+22,
and 9±11 vs. 17±16 ml/kg for control and rhTNFa groups at
-24, 3, 6, 24, 48 h, and 7 d, respectively.
Left ventricularfunction (Table IV). There were no signifi-
cant differences between the two groups in the baseline indices
of systolic myocardial contractile function (SW, %ES, or slope
and intercept of the preload recruitable stroke-work relation-
ship). LV stroke work, %ES, and the slope and x-intercept of
the preload recruitable stroke-work relationship were stable in
animals infused with heat-inactivated rhTNFa (Figs. 2 and 3).
At 3 and 6 h after the administration of active rhTNFa,
there was no evidence of systolic myocardial dysfunction as
assessed by analysis of SW and the slope and intercept of the
preload recruitable stroke work relationship. Fractional ejec-
tion shortening was significantly smaller than in the controls at
3, 6, 24, 48, and 72 h.
At 24 h, both SW and %ES were decreased significantly
from baseline. These changes were accompanied by a decrease
in the slope and a rightward shift (increase in x-intercept) of
the preload recruitable stroke-work relationship, so that at any
given LV end-diastolic dimension, LV stroke work was signifi-
cantly decreased (Fig. 3). By 48 h, SW and the slope and inter-
cept of the preload recruitable stroke-work relationship were
not significantly different from baseline, although the x-inter-
cept remained significantly different from the controls until
72 h.
The diastolic relationships between LV end-diastolic PTM
and either LV end-diastolic dimension (Fig. 4) or normalized
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* P < 0.05 as compared to baseline. $ P < 0.05 as compared to control.
Table III. Effects ofrhTNFa on Hemodynamic Indexes
Peak systolic LV End-diastolic LV Mean arterial Systemic vascular
Time Heart rate transmural pressure transmural pressure pressure dP/dt Cardiac index resistance index
h beats. min-' mmHg mmHg s_' liters* min-' kg' mmHg min- kg literf
Control
-24 102±13 126±4 13.5±1.2 111±4 3,112±473 0.14±0.02 868±284
0 96±15 128±9 14.1±2.5 110±8 3,011±403 0.13±0.02 858±277
3 95±18 127±9 13.4±3.2 111±6 3,126±433 0.13±0.02 837±139
6 95±16 123±6 11.2±2.7 108±4 3,227±367 0.13±0.03 819±228
24 92±18 126±5 12.1±3.1 110±3 3,037±366 0.12±0.02 946±252
48 96±14 124±8 11.2±1.7 109±7 3,094±375 0.14±0.04 842±382
168 95±23 132±4 13.9±3.3 117±4 3,275±124 0.13±0.03 947±294
rhTNFa
-24 100±16 133±8 13.5±5.5 115±7 2,803±290 0.11±0.01 934±58
0 99±17 136±10 13.6±5.2 114±11 2,971±319 0.12±0.01 920±119
3 117±25* 145±9** 9.3±4.9 117±9 3,280±715* 0.13±0.03 969±312
6 121±15** 132±8 10.8±5.1 108±13 2,984±597 0.13±0.02 879±122
24 133±19*t 112±16* 14.6±4.6 95±17* 1,789±454** 0.12±0.01 674±124*
48 110±15 127±8 16.1±5.7 113±7 1,972±310** 0.10±0.01 1,091±190
168 105±7 139±6 13.4±4.6 116±6 3,165±282 0.14±0.03 853±222
* P < 0.05 as compared to baseline. tP < 0.05 as compared to control group.
LV dimension (strain) (Figs. 5 and 6) were not significantly increase in Lo (Table IV). On the basis of the increase in Lo,
different at baseline between the control and active rhTNFa there was a significant leftward shift in the end-diastolic PrM-
groups. Administration ofheat-inactivated rhTNFa had no ef- strain relationship (Figs. 5 and 6), with significant differences
fect on these relationships (Fig. 4) or on unstressed LV dimen- from the controls evident at 24 and 48 h. The leftward shift of
sion (Table IV). the end-diastolic Prm-strain relationship is consistent with a
Administration of active rhTNFa elicited significant decrease in LV chamber compliance. By 72 h, the end-diastolic
changes in the diastolic relationships of the left ventricle that Prm-strain relationship returned to baseline (Figs. 5 and 6).
were initially manifested 24 h after infusion of the cytokine. Myocardial blood flow (Table V). There were no signifi-
These changes were characterized by a rightward shift of the cant differences in baseline subepicardial or subendocardial
LV end-diastolic Pm--dimension relationship (Fig. 4) and an QM between control and active rhTNFa groups. After the ad-
Table IV. Effects ofrhTNFa on Fractional Ejection Shortening, LV Stroke Work, Intercept ofthe Preload Recruitable Stroke-
Work Relationship, Lo, Slope ofthe Preload Recruitable Stroke- Work Relationship, and LV End-Diastolic Dimension
LV Slope of the preload Intercept of the preload Unstressed LV
LV fractional ejection recruitable stroke-work recruitable stroke-work LV end-diastolic
Time stroke work shortening relationship relationship dimension dimension
h ergs cm-2 % ergs *cm-2 mm-' mm
Control
-24 77,230±15,110 9.1±1.0 8,698±2,341 44.3±2.2 42.6±2.1 54.7±4.0
0 75,415±12,143 8.9±0.7 8,141+1,894 44.2±2.1 42.8±2.1 53.9±3.5
3 75,665±11,864 8.9±0.9 7,861±1,500 43.3±2.8 42.0±2.6 53.8±3.7
6 76,753±14,000 9.2±1.0 8,417±1,992 44.2±2.4 41.7±3.1 53.7±3.8
24 74,020±6,696 8.7±0.7 7,973±1,486 44.0±2.4 42.3±1.8 53.7±3.5
48 75,967±8,197 9.2±1.3 8,117±1,635 43.7±2.3 41.7±3.1 53.6±3.9
168 76,353±6,688 8.9±1.0 8,379±1,896 43.7±2.3 41.4±2.1 52.4±2.4
rhTNFa
-24 77,995±14,570 7.6±1.4 7,718±1,735 47.4±3.9 44.8±4.8 58.0±3.8
0 84,230±16,800 7.9±1.3 7,800±1,931 47.3±3.9 44.5±5.1 58.3±3.9
3 75,797±21,311 6.6±1.6* 8,430±2,193 47.9±3.5 45.3±4.8 57.2±4.4
6 67,281±17,841 6.7±1.6* 7,586±902 48.4±4.1 44.9±4.2 57.6±4.3
24 53,074±21,118*t 6.3±1.1*i 5,886±2,356*$ 49.9±4.1*$ 48.4±4.6** 59.2±4.8*
48 64,351±14,430 6.5±0.8* 6,619±2,321 49.7±4.6** 47.5±6.1 59.8±4.8t
168 85,863±21,386 7.7±1.6 8,877±2,928 47.7±6.2 45.1±8.2 57.6±6.4
* P < 0.05 as compared to baseline. t P <0.05 as compared to control group.
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Figure 2. Transmural pressure-minor axis dimension loops for indi-
vidual cardiac cycles. 1 d after the infusion of rhTNFa, ejection
shortening and peak-systolic PTm were reduced despite preservation
of preload (end-diastolic dimension). By 7 d, ejection shortening and
peak-systolic pressure were restored.
ministration of heat-inactivated or active rhTNFa, there were
no significant changes in subepicardial or subendocardial
blood flow.
6-keto-PGFIa (Table VI). There were no significant differ-
ences between the two groups in baseline venous plasma levels
of6-keto-PGFI . Administration ofactive rhTNFa elicited sig-
nificant increases in 6-keto-PGFa at 3 and 6 h. By 24 h, plasma
levels of 6-keto-PGFia returned to baseline.
Discussion
Effect ofrhTNFa on L Vfunction. Infusion ofrhTNFa resulted
in reversible systolic and diastolic LV dysfunction in chroni-
cally instrumented, conscious dogs. The onset of myocardial
dysfunction was not observed until 24 h after the infusion of
rhTNFa. At this time, HR was significantly increased, and
35 40 45 50 40 45 50 55
END-DIASTOLIC DIMENSION (mm)
Figure 4. End-diastolic relationships between PTm and LV dimension
in representative animals, 1 d after active infusion of rhTNFa the
PTM-dimension relationship was displaced to the right, with larger
dimension at any given PTm, including PTM = 0 mmHg. The position
of this relationship was restored at 7 d.
peak systolic PTM, PA, and SVRI were significantly decreased.
LV end-diastolic PTM (preload) was maintained at baseline lev-
els by infusing large volumes ofnormal saline. Despite the pres-
ence of myocardial dysfunction and decreased stroke volume,
Q was well maintained. By 72 h, LV function recovered to
baseline in all animals.
A hyperdynamic circulatory state with concomitant de-
pression ofmyocardial function similar to that observed in this
study has been described in studies of sepsis and septic shock
(24, 26-31 ). Thus, our data suggest that rhTNFa is capable of
eliciting the pattern ofhemodynamic derangements and myo-
cardial dysfunction characteristic of the sepsis syndrome. Our
findings are therefore consistent with the hypothesis thatTNFa
is a mediator ofsome ofthe circulatory and cardiac manifesta-
tions of sepsis and septic shock. In the present study, systolic
myocardial dysfunction was evidenced by a rightward shift and
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Figure 3. LV end-diastolic dimension-stroke work relationships in
representative animals. 1 d after infusion of active rhTNFa, the
end-diastolic dimension-stroke work relationship was shifted to the
right with a small decrease in slope. The position and slope of this
relationship were nearly restored at 7 d.
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Figure 5. End-diastolic relationships between PTM and normalized LV
dimension (strain) in representative animals. 1 d after the infusion
of active rhTNFa, the Prm-strain relationship was displaced to the left
with higher PrM at any given strain. By 7 d, the Prm-strain relation-
ship had returned close to its baseline position.
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Figure 6. Means ofend-diastolic PTM-strain data for the two groups of
dogs. The Prm-strain relationship of the group that received active
rhTNFa was displaced to the left of the PTM-strain relationship of the
control animals on day 1, with significantly smaller strains at 5 and
10 mmHg of pressure. On day 2, strains in the active rhTNFa group
were significantly smaller than strains in the control group at 10, 15,
and 20 mmHg.
Table VI. Effects ofrhTNFa on Plasma Levels of6-keto-PGF1,,
Time 6-keto-PGF,.
h pg/mi
Control
-24 97±167
0 113±191
3 102±183
6 71±129
24 71±118
48 81±135
168 86±173
rhTNFa
-24 57±68
0 31±57
3 548±299*t
6 1,110±258*t
24 84±101
48 70±107
168 53±81
* P < 0.05 as compared to baseline.
trol group.
* P < 0.05 as compared to con-
depression of the slope of the preload recruitable stroke work
relationship, so that at any given LV preload (end-diastolic
dimension), there was a significant reduction in the analogue
of LV stroke work. The reduction in stroke work was due to
both a decrease in fractional shortening of the minor axis di-
mension during the ejection phase of systole, and a decrease in
peak systolic LV pressure. Myocardial depression was suffi-
cient to decrease ejection shortening despite a concomitant re-
duction in SVRI (a proxy for LV afterload) and maintenance
of baseline levels of preload (end-diastolic PTM and EDL).
Fractional ejection shortening was depressed at 3 and 6 h, possi-
bly owing to either increases in afterload, decreases in preload,
or decreases in contractility that were not detectable in our
model. Systolic myocardial dysfunction at 24 h also was evi-
denced by a significant reduction in the maximal rate of rise of
LV pressure during isovolumic systole (dP/dt). This parame-
ter is sensitive to loading conditions, however, and may have
been influenced by the decrease in peak systolic PTM.
The most important finding of this study was the observa-
tion that infusion of rhTNFa caused significant diastolic dys-
function ofthe left ventricle characterized by these features: (a)
Table V. Effects ofrhTNFa on Myocardial Blood Flow
Time Subendocardial flow Subepicardial flow
h ml - min-'g
Control
0 1.14±0.20 0.96±0.08
48 1.07±0.32 0.93±0.30
168 1.10±0.54 0.94±0.50
rhTNFa
0 1.09±0.81 0.83±0.44
48 0.94±0.31 0.72±0.15
168 0.89±0.61 0.75±0.41
a significant increase in LV unstressed dimension, Lo0 (i.e.,diastolic creep); (b) a rightward shift of the LV end-diastolic
PTm-dimension relationship generated during vena caval oc-
clusions; and (c) a leftward shift of the LV end-diastolic PTM-
strain relationship. Recent experimental studies have demon-
strated LV dilatation 48 h after administration of rhTNFa(19). Whether this change represents physiologic LV dilatation
or a change in LV chamber compliance was investigated in our
model by analyzing changes in unstressed dimension and
strain (fractional extension from unstressed dimension). 24
and 48 h after the infusion ofrhTNFa, there was an increase in
unstressed dimension (creep) and a significant leftward shift of
the LV end-diastolic PTM-strain relationship, so that at any
given end-diastolic strain, there was a greater LV end-diastolic
PTM. The findings suggest that the administration of rhTNFa
alters the diastolic elastic properties ofthe LV wall, resulting in
a significant reduction in LV chamber compliance. Chamber
compliance can also be altered by changes in external con-
straints to filling (pressure and volume loading of the right
ventricle or increases in intrapericardial pressure [45]), how-
ever, there was no evidence for these mechanisms in the pres-
ent study. Specifically, right atrial filling pressures were not
significantly different over time or between control or rhTNFa
groups (data not shown). The finding that diastolic function is
impaired, suggests that the LV dilatation noted by us and by
Natanson et al. ( 19) is not simply dilatation ofthe left ventricle
along its normal pressure-volume relationship to compensate
for systolic dysfunction.
Stahl and colleagues (31 ) demonstrated diastolic creep with
decreased LV diastolic compliance during sepsis induced by
cecal ligation and puncture in dogs. Because the changes in
diastolic LV function elicited by rhTNFa are similar to those
observed in this canine model of sepsis, it is plausible to hy-
pothesize that TNFa is a mediator ofsepsis-induced alterations
in the diastolic mechanical properties of the myocardium.
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During the course of several days, there are three mecha-
nisms that could explain the rhTNFa-induced elongation of
the external diameter of the left ventricle at zero stress: (a)
elongation ofmyocardial fibers, (b) rearrangement ofthe inter-
stitial matrix, and (c) formation of myocardial edema. Studies
examining cardiac enlargement during models of ischemic in-
jury and hemodynamic overload have demonstrated that in-
creases in ventricular dimension can in part be accounted for
by changes in fiber length (reflected by changes in sarcomere
length [46-48 ] ), by slippage and realignment of the fibers (or-
derly rearrangement ofthe interstitial matrix [48, 49]), and by
disruption of the interstitial matrix (48, 50). Although elonga-
tion ofsarcomere length and slippage between fiber layers prob-
ably occurs during ventricular expansion related to physiologic
increases in preload, the elongation of dimension at a fixed
stress (zero) suggests a change in fiber length or fiber arrange-
ment that is not immediately reversible by physiologic restor-
ing forces. In the case of rhTNFa-induced diastolic dysfunc-
tion, it is unknown whether elongation of unstressed dimen-
sion represents injury to the myocardial fibers and contractile
proteins or disruption ofthe interstitial matrix. In the setting of
reversible contractile dysfunction associated with myocardial
stunning, extensive damage to the interstitial matrix has been
demonstrated (50). The interstitial injury accompanying myo-
cardial stunning is detectable within 3-4 h, and occurs in the
absence ofa local inflammatory response or myocardial necro-
sis. Invoking damage to the interstitial matrix as the cause of
the ventricular enlargement observed in the present study
would be compatible with the reversibility ofthe creep induced
by rhTNFa, but would not in itselfexplain the delayed onset of
creep.
The measurement of an external LV diameter with epicar-
dial dimension transducers includes the measurement of two
wall thicknesses. If infusion of rhTNFa elicited the formation
of myocardial edema with a concomitant increase in wall
thickness, an increase in the external anterior-posterior minor
axis dimension could have occurred in our experiments with-
out a true increase in the internal diameter and volume of the
left ventricle. We did not measure water content ofthe myocar-
dium or changes in wall thickness to exclude this possibility.
However, the large mass ofedema necessary to account for the
observed change in Lo would likely have caused far more severe
systolic dysfunction. For an extension ofLo from 4.5 to 4.8 cm
to occur on the basis of an increase in wall thickness only,
enough edema would have to be present in an equatorial LV
ring to increase its mass by - 20%. Previous studies have dem-
onstrated that, with a comparable increase in LV mass owing
to edema, cardiac output is reduced - 50% at fixed preload
(left atrial pressure = 15 mmHg) (51 ).
Whether TNFa-induced myocardial injury is primarily to
myocytes or to the interstitial matrix, the intermediate mecha-
nisms underlying this injury remain unknown. Both direct ef-
fects ofTNFa on the myocardium or effects by secondary medi-
ators seem plausible. It is unlikely that myocardial depression
in our study was the result ofrhTNFa-induced systemic meta-
bolic abnormalities. At the time of maximum myocardial de-
pression (24 h), animals were only mildly acidemic (pH
7.31±0.03). It is unlikely that this level ofacidosis can account
for the observed degree of systolic dysfunction myocardial de-
pression, since at 6 h, when systemic acidosis was more severe,
there was no evidence of myocardial depression. Ventricular
dysfunction also cannot be attributed to changes in subendocar-
dial or subepicardial blood flow. Both systolic and diastolic
dysfunction were evident at 48 h, when QM was not signifi-
cantly less than baseline.
Myocardial injury induced by TNFa may depend upon the
recruitment and activation of neutrophils. This hypothesis is
consistent with these findings: (a) TNFa enhances margina-
tion and infiltration of neutrophils through endothelium (52,
53); (b) TNFa promotes adhesion of neutrophils to cardiac
myocytes (54); and (c) neutrophils participate in ischemic
myocardial injuries that result in both cell death and reversible
contractile dysfunction (55-60). There is also evidence that
TNFa promotes systemic and local release ofsecondary media-
tors from white blood cells (61-65) that could potentially com-
promise myocardial contractile function (66-70). The finding
in this study that the onset of ventricular dysfunction occurs
6-24 h after administration ofrhTNFa, could be explained by
neutrophil activation and subsequent infiltration into the myo-
cardium with systemic and local release of mediators over a
period of several hours.
Recent in vitro studies have described a direct effect of
TNFa on the sympathomimetic stimulation of myocardial
contractile function. Myocytes exposed to TNFa for 72 h dem-
onstrate a decrease in isoproterenol-stimulated augmentation
of contractile activity and production of cAMP (34). These
effects occur without a change in the density or affinity of fi-
adrenergic receptors. The response to forskolin, an inhibitor of
adenylate cyclase, is not affected by exposure to TNFa (34).
These data suggest that myocardial cells express receptors for
TNFa, which when activated, elicit derangements in the ,B re-
ceptor-regulatory GTP binding protein-adenylate cyclase
transduction system ( 71 ).
Effects ofrhTNFa on hemodynamics, prostacyclin release,
and arterial oxygenation. Consistent with previous reports by
others (22), we observed a marked increase in circulating levels
of6-keto-PGFia after infusion ofrhTNFa. We measured levels
of this prostanoid as an internal check to document that the
cytokine was indeed active. Also consistent with previously
published results (21, 22) was our observation that infusion of
rhTNFa elicited fever and arterial hypoxemia, and decreased
SVRI during the early (3-24 h) period after infusion.
Critique of experimental methods. The assessment of sys-
tolic and diastolic myocardial function in this study relied
upon the analysis of a single external ventricular dimension
(anterior-posterior axis diameter). Changes in this linear di-
mension have been substituted for changes in LV volume. Sys-
tolic stroke work is a pressure-volume integral rather than a
pressure-dimension integral, and a more complete description
of LV chamber compliance requires analysis of the diastolic
pressure-volume relationship, rather than a pressure-diameter
relationship. However, Rankin et al. (72) have demonstrated
in a similar experimental preparation that changes in the ante-
rior-posterior minor axis dimension during the cardiac cycle
are highly correlated with changes in LV volume. We have
validated under baseline conditions that changes in minor axis
dimension during the ejection phase are highly correlated with
changes in stroke volume, measured independently with the
pulmonary artery flow probe used in this study (F. D. Pagani,
unpublished observations).
The present study leaves some uncertainty in the time of
onset of mechanical dysfunction of the left ventricle. Because
no data were collected between 6 h and 24 h, the true onset of
LV dysfunction may have occurred between these two time
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points. Latent LV contractile dysfunction at earlier time points
may have been masked by adrenergic stimulation. Further-
more, the statistical power of this study was limited by the
availability of only a seven- animal X five-animal matrix of
data for final analysis.
Finally, rather than obtaining tissue from ventricles for his-
tologic and biochemical analysis at the time of their maximal
dysfunction (24-48 h), we elected to document the reversibil-
ity of ventricular dysfunction and the time course of recovery.
Future studies in which tissue is harvested 24-48 h after the
administration of rhTNFa will therefore be necessary to eluci-
date the histologic and biochemical substrates of the myocar-
dial injury.
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